Kancera

Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

CEO statement

“Kancera has made significant progress in advancing its development programs within inflammation and cancer. We truly believe that our candidate drugs can make a difference for many patients. but the challenging capital market conditions makes external financing not possible near term.”

Peter Selin, CEO Kancera